correction sickle cell disease adult mice interference fetal hemoglobin silencing 
persistence human fetal hemoglobin hbf alphagamma adults lessens severity sickle cell disease scd beta-thalassemias show repressor bcl11a required vivo silencing gamma-globin expression adult animals yet dispensable red cell production bcl11a serves barrier hbf reactivation known hbf inducing agents proof-of-principle test bcl11a potential therapeutic target demonstrate inactivation bcl11a scd transgenic mice corrects hematologic pathologic defects associated scd high-level pancellular hbf induction thus interference hbf silencing manipulation single target protein sufficient reverse scd 
